-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
-
The Rising Cost of Lung Cancer Therapies: What Are the Global Implications?
By Doreen A. Ezeife, MD, FRCPC; Malcolm Ryan; and Natasha B. Leighl, MD, MMSc, FRCPC, FASCO Posted: March 1, 2019 Dramatic improvements in lung cancer outcomes can be attributed to recent advances in novel targeted therapy and immunotherapy. As the treatment paradigm for lung cancer evolves, concerns about the rising cost of these novel therapeutics…
-
An Interview with Dr. Federico Cappuzzo: Checkpoint Inhibitors Have Replaced Old Strategies
Posted: March 1, 2019 Federico Cappuzzo, MD, PhD, has been the director of Medical Oncology at AUSL della Romagna, Ravenna, Italy, since April 2016; in January 2017 he became the director of the Hematology and Oncology Department. The author of more than 200 papers, Dr. Cappuzzo is an extremely active member of the IASLC, having…
-
Cancer Research Innovator, Trailblazer, and Mentor Dr. Waun Ki Hong Dies
Posted: March 1, 2019 Waun Ki Hong, MD, the “father of chemoprevention” and renowned cancer researcher and mentor, died on January 2, 2019, at the age of 76. Dr. Hong’s illustrious career began in the South Korean Air Force as a flight surgeon during the Vietnam War. After his military service, Dr. Hong completed his…
-
Thoughts on IMpower 150: Latest FDA Approval for Atezolizumab Misses the Mark
Posted: March 1, 2019 On December 6, 2018, the U.S. Food and Drug Administration (FDA) approved atezolizumab in combination with bevacizumab and chemotherapy, specifically paclitaxel and carboplatin, in advanced nonsquamous NSCLC. As part of a larger phase III trial, this combination (PCBA) proved superior to the “standard” combination of bevacizumab/paclitaxel/carboplatin (PCB). In the wild-type population,…
-
Valerie W. Rusch, MD, FACS
Posted: March 1, 2019 Valerie W. Rusch, MD, FACS, was elected to serve as the 2018-2019 president-elect of the American College of Surgeons. Dr. Rusch is the vice chair for Clinical Research in the Department of Surgery and the Miner Family Chair in Intrathoracic Cancers at Memorial Sloan Kettering Cancer Center and professor of surgery…
-
The IASLC’s Spotlight on Screening
By James L. Mulshine, MD, and John K. Field, PhD, FRCPath Posted: March 1, 2019 The IASLC is supporting a new early thoracic CT image archive to encourage both quality measures and research for early lung cancer detection and management. This effort, the IASLC’s Early Lung Imaging Confederation (ELIC), is planned to have global reach…
-
IASLC SCLC Meeting Program, Faculty to Reflect the Field’s Pivotal, Recent Major Advances
By Charles M. Rudin, MD, PhD Posted: March 1, 2019 2019 IASLC Small Cell Lung Cancer Meeting April 3-5 • New York, New York Memorial Sloan Kettering Cancer Center The 2019 IASLC Small Cell Lung Cancer (SCLC) Meeting will be held at Memorial Sloan Kettering Cancer Center in New York, New York, April 3 to…
-
Nursing Care’s Technological Patient-Care Transformation
By John McPhelim, RN, BSc (Hons) Posted: March 1, 2019 Mr. John McPhelim Nursing—particularly communication—in lung cancer care is transforming as a result of the innovative use of supportive health technologies. Cell phones, tablets, laptops, and desktop computers are growing increasingly popular in the use of safety monitoring and communication with patients across…
-
Ongoing Clinical Challenges: Defining Immunotherapy Benefit for Patients With NSCLC and Poor Performance Status
This article is the first in a two-part series on ongoing challenges using immunotherapy in special populations. The second part of this series focuses on elderly patients. By Valérie Gounant, MD, and Elisabeth Quoix, MD, PhD Posted: December 11, 2019 Since the beginning of the 21st century, there have been two major innovations in the treatment of…
View ILCN Archives
Provider Resources
Popular Articles